COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,510 Articles (22,870 medRxiv, 8,640 bioRxiv)

Most recent first Previous |  Page 24: Articles 231-240  | Next

Multiorgan Outcomes Following COVID-19 Vaccine vs Infection: 30M Analysis
Toraih, E. A., Bruce, D., Hussein, M. H., Aiash, H., Thomas, S. J.
10.64898/2026.01.30.25343064 — Posted: 2026-02-03
A Cross-Sectional Study of COVID-19 Vaccine Hesitancy and Behaviours among People Living with HIV in British Columbia
Ejiegbu, A. E., Shariati, B., Little, J., Brondani, M.
10.64898/2026.01.31.26345295 — Posted: 2026-02-03
SEVA: An externally driven framework for reproducing COVID-19 mortality waves without transmission feedback
Varming, K.
10.64898/2026.01.30.26345245 — Posted: 2026-02-03
Preclinical and Clinical Study of Efficacy of NAOQ19 against SARS-COV2: A Comprehensive Evaluation
Subramanian, S., Garhyan, J., Mony, V., Pattabiraman, S., Kanchibhotla, D.
10.64898/2026.01.27.26344593 — Posted: 2026-02-02
Risk of interstitial lung disease in COVID-19 patients with autoimmune diseases treated with antiviral agents: a retrospective cohort study
Cheng, I.-H., Huang, X., Wang, Y.-H., Hung, Y.-m., Wei, J. C.-C.
10.64898/2026.01.30.26345205 — Posted: 2026-02-01
Evaluating the Usability of Co-Created Public-Facing Knowledge Mobilization Resources for the Canadian Guidelines for Post COVID-19 Condition
Elliott, S. A., Cyrkot, S., Scott, S. D., Travis, H., Motilall, A., Wiercioch, W., Pardo, J. P., Schunemann, H. J., Nieuwlaat, R., Hartling, L.
10.64898/2026.01.29.26344622 — Posted: 2026-01-30
Adverse Events After LP.8.1-Containing COVID-19 mRNA Vaccines
Hviid, A., Thiesson, E. M., Andersson, N. W.
10.64898/2026.01.25.26344612 — Posted: 2026-01-30
Displayed and Encoded Antigens on Adenovirus Vectors Optimize Humoral and Cellular Immune Responses in Rhesus Macaques
Li, Z., Dicks, M. D. J., Rose, L. M., Russell, R. A., McMahan, K., Lasrado, N., Nkolola, J., Borducchi, E., Liu, J., Biswas, S., Barouch, D. H.
10.64898/2026.01.29.702655 — Posted: 2026-01-30
Association Between SARS-CoV-2 Mutations and Disease Severity Reveals Risk and Protective Effects Among Community-Sampled Patients in Israel
Eliyahu, H., Barda, N., Mandelboim, M., Lustig, Y., Zuckerman, N. s.
10.64898/2026.01.26.26344903 — Posted: 2026-01-29
A comparison of observation models for statistical inference of emerging disease transmission dynamics: Application to SARS-CoV-2
Domenech de Celles, M., Kramer, S. C.
10.64898/2026.01.27.26344924 — Posted: 2026-01-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).